UroCure Expands SUI Sling Portfolio with the Nationwide Launch of the ArcSP and ArcTO Slings

UroCure and LiNA Medical USA are pleased to announce the nationwide launch of UroCure’s two latest innovations of surgical solutions for female stress urinary incontinence: the ArcSP Suprapubic Sling System and the ArcTO Transobturator Sling System.  These two additions complement the current UroCure ArcTV® Transvaginal Sling on the market. ArcSP will now provide a top-down, retropubic approach and ArcTO will accommodate surgeons that prefer an outside-in, transobturator approach. All three systems are based on AMS’ best-in-class slings, while incorporating UroCure’s laser cut sling with its patented stabilizing suture. The absorbable stabilizing suture is a key innovation of UroCure’s sling designed to maintain its open pore structure and to protect the sling from deformation during placement, tensioning, and sheath removal. Read more.

Source: PRNewswire, January 25, 2024

Unveiling the Link Between Financial Strain and Lower Urinary Tract Symptoms

The association between financial strain and lower urinary tract symptoms LUTS and impact is caused by a lack of health care utilization and comorbidities, according to a recent study published in the American Journal of Obstetrics & Gynecology. LUTS such as urinary incontinence (UI), nocturia, frequent urination, or difficulties with bladder emptying often adversely impact quality of life and increase the risks of depression and anxiety. Data has indicated the risk of LUTS is increased by social determinants of health (SDOH) such as housing insecurity, food insecurity, financial insecurity, difficulty finding employment, and unreliable transportation. Read more.

Source: Contemporary OB/GYN, January 19, 2024

Understanding the Link Between Urinary Incontinence in Women and Disability Risk: Insights from Recent Medical Research

Urinary incontinence, a condition that affects millions of women worldwide, may have more severe implications than previously thought. A recent study from the Rush University Medical Center has added a new dimension to our understanding of this common health issue. According to the study, urinary incontinence in women is linked with a higher risk of disability. This finding is significant and has implications for both the management and treatment of urinary incontinence in women. Read more.

Source: Medriva, January 12, 2024

female doctor

Medical Device Maker Boston Scientific to Buy Axonics for $3.7 Billion

Medical device maker Boston Scientific (BSX.N), said on Monday it had agreed to buy Axonics Inc (AXNX.O), for $3.7 billion, gaining access to devices used to improve bladder function.  The deal marks Boston Scientific’s entry into sacral neuromodulation, a minimally invasive procedure used in the treatment of overactive bladder and fecal incontinence, and is the latest in efforts to scale up its urology business. Read more.
Source: Reuters, January 8, 2024
clinical medical

UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today it has reached a significant milestone: the complete treatment cohort in the first-of-its-kind clinical feasibility study has successfully reached the six-month primary endpoints.  The feasibility assessment of the UroActive System was completed through a prospective multicenter clinical study. UroActive is the first smart automated artificial urinary sphincter (AUS) to treat SUI, and the only one to reach this critical milestone.  Read more.

Source: PRNewswire, December 13, 2023

women exercising

JUNOFEM Seeks FDA Approval for Innovative ‘femfit’ Incontinence Device in the US

JUNOFEM, a medical equipment supplier based in Auckland, New Zealand, has taken a significant step toward introducing their innovative ‘femfit’ female incontinence device to the American market by applying for FDA approval. After two years of dedicated work on their 510(k) pre-market submission, JUNOFEM aims to gain access to the US market upon FDA approval.  The femfit® Pelvic Floor Training Tool is a cutting-edge device designed for female pelvic floor muscle exercises. Read more.

Source: UniverseNews Network, December 7, 2023

Female Incontinence: A Public Health Crisis?

Women’s health has a long history of being sidelined—that’s no great secret. Women’s health issues cloaked in embarrassment are uniquely at risk of being overlooked or ignored. Urinary (UI) and fecal incontinence (FI) are among them. Shame often keeps women from speaking about bothersome symptoms, which contributes to today’s grim reality: the adult diaper market now exceeds the market for baby diapers. With 62% of adult women living with bladder leaks, I feel female incontinence has reached the level of a public health crisis. Read more.

Source: MedCity News, December 6, 2023

medical research

Urology in the Lab: Researchers link EBV to Multiple Sclerosis

Urology in the Lab starts off with data from a study that very strongly implicates Epstein-Barr virus (EBV) as the causative agent underlying multiple sclerosis (MS), a demyelinating disease that often finds its way into the urology clinic due to neurogenic bladder that can develop during the course of disease. Read more.

Urology Times, November 27, 2023

imaging brain head

Medical Mysteries: Dizzy and Off-balance, She Searched for the Cause

The first sign of trouble was difficulty reading. In late 2014 Cathy A. Haft, a New York real estate broker who divides her time between Brooklyn and Long Island, thought she needed new glasses. But an eye exam found that her prescription was largely unchanged.  Bladder problems came next, followed by impaired balance, intermittent dizziness and unexplained falls. By 2018 Haft, unable to show properties because she was too unsteady on her feet, was forced to retire. Read more.

Source: Washington Post, November 25, 2023

drugs for overactive bladder (OAB)

Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI).  Following this clearance, Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study in the first half of 2024. The study will evaluate the safety, tolerability, and efficacy of VMB-100 in female subjects with stress urinary incontinence, a highly common condition resulting in involuntary leakage of urine due to a weakened urinary sphincter muscle. Read more.

Source: Pharmaweb.com, November 17, 2023